Dignitana AB Publishes Q1 2020 Interim Report

Growth of 23 percent as demand for DigniCap increases


Financial highlights

  • Group revenue amounted to 12 478 TSEK (10 106 TSEK), an increase of 23 percent over the same period in 2019 and an increase of 24 percent over Q4 2019.
  • EBITDA amounted to -8 761 TSEK (-2 799), a change of 213 percent over the same period in 2019 and an improvement of 23 percent compared to Q4 2019.
  • Earnings per share is - 0.23 SEK compared to -0.11 SEK in the same period 2019.
  • Average Daily Treatment Revenue (ADTR)* increased to 118 TSEK (88 TSEK) an increase of 35 percent over the same period in 2019 and an 8 percent increase over Q4 2019.

Business highlights

  • An Extraordinary General Meeting was held 10 February 2020 which resolved on one issue, the transfer of warrants to key persons in Dignitana Inc. in accordance with the proposal by the Board of Directors.
  • Sponsorship of U.S. events with Susan G. Komen®, the largest breast cancer advocacy non-profit in the world.
  • Signed distribution agreement with MedPhy Technologies in India to enable access to this important and growing market.
  • Launched DigniCap Mobile App for patient-centered care.

Significant events after the period

  • The Company obtained an unsecured loan in the amount of $353 800 USD from the Payroll Protection Program, a COVID-19 economic stimulus initiative in the United States.
  • With the final $500 000 USD received after the period, funding was completed for the new loan received from Union Business Leasing in the total amount of $1,5 million USD.
  • Dignitana signed a master contract with Hartford HealthCare in the U.S.
  • The Company signed a master contract in the U.S. with American Oncology Network.
  • Dignitana signed contracts for 5 new locations with U.S. medical providers.

Key Figures

DIGNITANA GROUP Q1 2020 Q1 2019 Full Year 2019
Net revenues, TSEK 11 393 9 237 40 699
Total revenues, TSEK 12 478 10 106 42 546
Net profit after financial items, TSEK -12 755 -5 270 -37 950
Cash and bank balances, TSEK 8 768 21 715 19 433
Earnings per share before and after dilution, SEK -0,23 -0,11 -0,76
Average Daily Treatment Revenue*, TSEK 118 88 107

* ADTR includes pay-per-treatment revenue from patients and facilities. Does not include lease revenue or disposable sales.

All financial reports are available at www.dignitana.com/investor-relations/financial-reports/


This information is such information that Dignitana AB (publ) is required to disclose in accordance with the EU Market Abuse Regulation. The information was submitted, through the contact person below, for publication on 28 May 2020 at 0830 CET.

For More Information Contact

Investor Relations +1 469 518 5031 investorrelations@dignitana.com

About Dignitana

Dignitana AB is the world leader in clinically superior scalp cooling technology. The company produces The DigniCap® Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and patient comfort. Hailed internationally as a life-changing medical advancement for cancer patients, The DigniCap Scalp Cooling System was invented in 1999 by a Swedish Oncology nurse and has been available in Europe since 2001.  Dignitana AB is listed on Nasdaq First North Growth Market in Sweden with headquarters in Lund, Sweden and operations based in Dallas, Texas in the United States.  Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Learn more at www.dignitana.se and www.dignicap.comEric Penser Bank AB, Certified Adviser, Box 7405,103 91 Stockholm Phone: +46 8-463 83 00 certifiedadviser@penser.se www.penser.se